Clinical validation of T1ρ mapping for the assessment of hepatic fibrosis in patients with chronic liver disease
Question Accurate non-invasive assessment of hepatic fibrosis remains challenging, particularly in the presence of steatosis, where MRI biomarkers such as native T1 and ECV fraction are limited. Findings T1ρ mapping outperformed native T1 and ECV for identifying significant fibrosis and maintained robust accuracy in the presence of hepatic steatosis. Clinical relevance T1ρ mapping offers a robust, non-invasive MRI biomarker for assessing hepatic fibrosis across the full spectrum of CLD, including SLD, with superior accuracy to native T1 and ECV and reduced influence from hepatic fat infiltration.
Authors
- Daniel Kuetting (ORCID: https://orcid.org/0000-0001-6520-1020)
- Julian Alexander Luetkens (ORCID: https://orcid.org/0000-0002-7715-4636)
- Dmitrij Kravchenko (ORCID: https://orcid.org/0000-0003-0331-2045)
- Tatjana Dell (ORCID: https://orcid.org/0000-0002-2835-8560)
- Claus Christian Pieper (ORCID: https://orcid.org/0000-0002-0893-1200)
- Narine Mesropyan (ORCID: https://orcid.org/0000-0002-5871-3965)
- Alexander Isaak (ORCID: https://orcid.org/0000-0003-2016-6166)
- Philipp Ludwig Lutz (ORCID: https://orcid.org/0000-0002-4921-200X)
- Fabian Kaiser (ORCID: https://orcid.org/0000-0002-0335-2859)
- Johannes Chang (ORCID: https://orcid.org/0000-0001-9635-8901)
- Christoph Katemann
- O. Weber (ORCID: https://orcid.org/0000-0002-2569-0875)
- Can Yueksel
Institutions
- University Hospital Bonn (DE)
- Universitätsklinikum Aachen (DE)
- Philips (Germany) (DE)
Publication Details
- Journal
- European Radiology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1007/s00330-025-12225-5
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00